Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma

Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma

Abstract Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin’s lymphoma characterized by poor prognosis. The complexity of MCL pathogenesis arises from aberrant activities of diverse signaling pathways, including BTK, PI3K–AKT–mTOR and MYC-BRD4. Here, we report that MCL-related signaling pathways...

Full description

Bibliographic Details
Main Authors: Kendra R. Vann, Dhananjaya Pal, Audrey L. Smith, Namood-e Sahar, Maddeboina Krishnaiah, Dalia El-Gamal, Tatiana G. Kutateladze
Format: Article
Language:English
Published: Springer 2022-01-01
Series:Molecular Biomedicine
Subjects:
Mantle cell lymphoma
BRD4
Bromodomain
Inhibitor
Bruton's tyrosine kinase
Phosphatidylinositol-3 kinase
Online Access:https://doi.org/10.1186/s43556-021-00066-9

Internet

https://doi.org/10.1186/s43556-021-00066-9

Similar Items